Get the Stockscreener App
12.13
3.73%
-0.47
After Hours:
12.25
0.12
+0.99%
Monte Rosa Therapeutics Inc stock is traded at $12.13, with a volume of 1.60M.
It is down -3.73% in the last 24 hours and down -19.29% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$12.60
Open:
$12.57
24h Volume:
1.60M
Relative Volume:
1.14
Market Cap:
$1.03B
Revenue:
$42.95M
Net Income/Loss:
$-130.01M
P/E Ratio:
-7.4518
EPS:
-1.6278
Net Cash Flow:
$-19.66M
1W Performance:
-13.79%
1M Performance:
-19.29%
6M Performance:
-23.03%
1Y Performance:
+75.04%
1-Day Range:
$12.02
$12.64
1-Week Range:
$12.02
$14.38
52-Week Range:
$6.23
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
12.13 | 1.20B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone - Yahoo Finance
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - moomoo.com
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
GLUE News | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
GLUE stock gains on investor conference plans and Monte Rosa outlook - ad-hoc-news.de
Six new hires get stock awards from Monte Rosa - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive - Sahm
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
Monte (GLUE) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Current Update; Session Move - vinanet.vn
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - theglobeandmail.com
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - marketbeat.com
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):